Newly funded drug linked to tachycardia, hep B and infection

The TGA has updated its safety advice for ibrutinib after reviewing latest research on the medicine’s risks and effects Ibrutinib, marketed in Australia as Imbruvica, is used for the treatment of certain types of blood cancers, including mantle cell lymphoma and Waldenstrom's macroglobulinaemia chronic lymphocytic leukaemia (CLL, which includes small lymphocytic lymphoma). Just last month